The BSG is managed by a Board of Trustees with support from advisory groups relating to specific projects:
Craig Gerrand is a Consultant Orthopaedic Surgeon and Clinical Lead for the North of England Bone and Soft Tissue Tumour Service based in Newcastle Upon Tyne Hospitals NHS Foundation Trust.
He has been a Consultant since 2001, runs a clinical practice for patients with bone and soft tissue sarcomas and has developed a clinical research programme to complement the service.
He has experience of working with patients and families as a Trustee of the Bone Cancer Research Trust and has served on the NCRI sarcoma studies group, the NCIN clinical reference group and the NHS Clinical Reference Group for Specialist Commissioning.
He has been a Trustee of the British Sarcoma Group since it became a charitable incorporated organisation and was delighted to be invited to become BSG President in 2016.
Dr Beatrice Seddon is Consultant Clinical Oncologist on the Sarcoma Unit at University College Hospital, specialising soft tissue and bone sarcomas.
She currently lectures and teaches on the management of sarcomas, and is actively involved in clinical research projects in this area.
She is a member of the EORTC Soft Tissue and Bone Sarcoma Group and the NCRN Sarcoma Clinical Studies Group.
She has a special interest in gynaecological sarcomas, GIST, and radiotherapy for sarcomas, and is currently the chief investigator for the UK NCRN IMRiS phase II trial of intensity modulated radiotherapy in sarcoma.
I qualified in 1996 and worked in orthopaedics, until in 1998, I took up the role as a sister in cancer and palliative care at a local hospice working in the community. In 2008, I was appointed as Sarcoma CNS in 2008 and work as part of the East Midlands Sarcoma Service based in Leicester.
I see all patients diagnosed with sarcoma at the point of diagnosis and remain their key worker throughout.
Since taking up the post, I help set up and run the East Midlands Sarcoma Support Group, held monthly.
I am the co-founder of the National Sarcoma Forum for sarcoma specialist nurses and allied health care professionals.
In 2014, I became a Board member for the British Sarcoma Group.
I have an interest in service improvement and care delivery involved in – developing a patient information pathway, patient satisfaction audit, ambulatory sarcoma chemotherapy, wellbeing and survivorship, working locally and nationally with sarcoma units particularly improving coordination and communication with sarcoma units to help with the patients treatment planning. I work closely with Sarcoma UK and Bone Cancer Research Trust as well as patient volunteers.
Prof Ian Judson graduated in Natural Sciences from Cambridge University in 1972, studied medicine at King’s College Hospital Medical School and medical oncology at the Royal Marsden Hospital.
He was awarded an MD from Cambridge in 1988 for work on cancer pharmacology and was appointed Senior Lecturer at The Institute of Cancer Research / Royal Marsden Hospital in 1989. He was made Professor of Cancer Pharmacology in 2001.
He has published over 250 peer-reviewed papers plus numerous reviews and editorials, focused on new anticancer drug development and soft tissue sarcomas.
He has extensive experience in the management of sarcomas and has conducted many clinical trials including one of the initial studies of imatinib in the treatment of gastrointestinal stromal tumor.
He has held the positions of President, Connective Tissue Oncology Society, President, British Sarcoma Group and Chairman, EORTC Soft Tissue and Bone Sarcoma Group (STBSG), of which he is currently Treasurer.
He was until recently Head of the Sarcoma Unit at the Royal Marsden.
Mr Hayes is a Consultant General Surgeon and Surgical Oncologist on the Sarcoma Unit and the Skin Unit. He qualified at Oxford University and St Bartholomew's Hospital, London, and undertook his surgical training in London and a PhD in Washington DC.
Mr Hayes has a specialist practice in soft-tissue sarcoma and advanced melanoma, and operates on over 150 cases of sarcoma and another 150 of cases of advanced malignant melanoma a year. Mr Hayes leads the isolated limb perfusion programme which provides a national service for regional chemotherapy for patients with advanced limb malignancy .
Mr Hayes is Head of The Royal Marsden's Skin Unit, Chair of the South West London Sarcoma Tumour Working Group and Clinical Lead for the Rare Cancers Clinical Business Unit at The Royal Marsden.
Mr Hayes was awarded a Hunterian Professorship in 2002 for his research into angiogenesis as a therapeutic approach for cancer. In 2014 he was appointed as Honorary Associate Faculty at the Institute of Cancer Research and he is Team Leader of the Sarcoma and Melanoma Surgery Research Group at the ICR. He has a laboratory research program investigating new therapies for extremity malignancies using isolated limb perfusion and he has published widely in the fields of sarcoma and melanoma.
Lindsey Bennister is Chief Executive at Sarcoma UK, the only national cancer charity focusing on all types of sarcoma. She has over 25 years’ experience of working in the voluntary health sector. She joined Sarcoma UK in 2010 as its first Chief Executive (and first member of staff). She has overseen the significant growth in profile and income of the charity and the delivery of its first Strategy: “Transforming the Landscape for Sarcoma 2014-2020.”
Lindsey previously worked in a senior role at Prostate Cancer UK for seven years where she was responsible for a team delivering research, information & support, policy & campaigning, health professional education and marketing communications. Lindsey’s career includes roles at the Neurofibromatosis Association, the Long-term Medical Conditions Alliance (now National Voices), and Asthma UK.
Lindsey is a Fellow of the RSA (Royal Society for the encouragement of Arts, Manufactures and Commerce).
Adam Dangoor is a medical oncologist at the Bristol Cancer Institute specialising in the treatment of sarcoma, lung cancer, and mesothelioma, as well as hepatobiliary and upper GI malignancies.
Adam has been a consultant in Bristol since 2008 and before that completed his oncology training at the Christie Hospital in Manchester. As a Cancer Research UK Clinical Fellow he took part in running trials of cancer vaccines targeting colorectal cancer and melanoma.
Prior to that he has worked as a doctor at a number of trusts in the UK, New Zealand, and Australia.
As well as being a BSG Board Member he is a co-author of the latest soft-tissue sarcoma guidelines, due for publication shortly, and is the medical lead for the BSG Conference 2017 in Bristol.
Sarah is from The Christie NHS Foundation Trust, Manchester.
Sarah trained in Bristol and has worked in Newcastle, Australia and Manchester. She has been working at the Christie for 20 years in medical oncology, 17 years as a clinical research nurse in GI, renal, haematology and the last 9 years of which were in sarcoma.
More recently Sarah has joined the proton beam service here at the Christie as a nurse clinician, working as part of a team of specialist clinicians and AHP in developing the UK first proton beam service.
This specialist type of radiotherapy often forms part of the treatment for sarcoma patients, part of her new role will be to liaise with specialist sarcoma teams across UK to develop services and care pathways for sarcoma patients having this treatment.
Owen is a Consultant Clinical Oncologist, Velindre Cancer Centre, Wales.